Rheumatology Network's Top 5: January 7, 2022
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending January 7, 2021.
Rheumatoid Arthritis Quiz: RA and the Lungs
Treatment for rheumatoid arthritis has been associated with the development and worsening of some lung conditions. Test your knowledge with this quiz.
Click the image to view the story.
Efficacy and Safety of Tofacitinib Not Impacted by Dose-Switching
While patients with rheumatoid arthritis may benefit from either increasing or decreasing their dosage of tofacitinib, post-hoc analysis indicates that safety and efficacy of the medication is not impacted by these changes.
Click the image to view the story.
TNFi Treatment Increases Risk of Antimicrobial Usage in Patients With RA
An increased frequency of serious infections and antimicrobial prescriptions was seen in patients with rheumatoid arthritis currently being treated with a TNFi.
Click the image to view the story.
Safety Profile Similar in Upadacitinib and Adalimumab for Patients With PsA
“As the therapeutic landscape for PsA evolves, evaluating the long-term safety of treatments is essential to understand benefit–risk profiles and inform patient care,” investigators explained.
Click the image to view the story.
COVID-19 Booster Dose May Enhance T-cell Immune Response in Rituximab-Treated Patients With RA
While patients with rheumatoid arthritis on rituximab therapy have been reported to have insufficient serological responses to the COVID-19 vaccine, T cells, which protect against severe COVID-19, may be elevated after a third dose.
Click the image to view the story.
